Adjuvant therapy (AT) with raltitrexed (RAL) in colorectal cancer (CRC) patients (pts) intolerant of 5-fluorouracil (5FU).

被引：0
|
作者：
Wilson, K. S.
Barnett, J. B.
Gill, S.
Khoo, K. E.
Fitzgerald, C. A.
机构：
[1] British Columbia Canc Agcy, Victoria, BC, Canada
[2] British Columbia Canc Agcy, Kelowna, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3571
引用
收藏
页码：163S / 163S
页数：1
相关论文
共 50 条
  • [31] The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer
    Zalcberg, JR
    Siderov, J
    Simes, J
    ANNALS OF ONCOLOGY, 1996, 7 (01) : 41 - 46
  • [32] A role for levamisole (LEV) in the adjuvant treatment of stage III colon cancer: A randomized trial of 5-fluorouracil (5FU) and LEV vs 5FU alone
    Catalano, V
    Cascinu, S
    Latini, L
    Mattioli, R
    Marcellini, M
    Pancotti, A
    Bascioni, R
    Torresi, U
    Silva, RR
    Pieroni, V
    Giorgi, F
    Testa, I
    Sturba, F
    Ferretti, B
    Catalano, G
    Cellerino, R
    ANNALS OF ONCOLOGY, 2000, 11 : 66 - 66
  • [33] PHARMACOKINETICS AND PHARMACODYNAMICS OF LOCOREGIONAL 5-FLUOROURACIL (5FU) IN ADVANCED COLORECTAL LIVER METASTASES
    GOLDBERG, JA
    KERR, DJ
    WILLMOTT, N
    MCKILLOP, JH
    MCARDLE, CS
    BRITISH JOURNAL OF CANCER, 1988, 57 (02) : 186 - 189
  • [34] Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer
    Gusella, M.
    Frigo, A. C.
    Bolzonella, C.
    Marinelli, R.
    Barile, C.
    Bononi, A.
    Crepaldi, G.
    Menon, D.
    Stievano, L.
    Toso, S.
    Pasini, F.
    Ferrazzi, E.
    Padrini, R.
    BRITISH JOURNAL OF CANCER, 2009, 100 (10) : 1549 - 1557
  • [35] Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer
    M Gusella
    A C Frigo
    C Bolzonella
    R Marinelli
    C Barile
    A Bononi
    G Crepaldi
    D Menon
    L Stievano
    S Toso
    F Pasini
    E Ferrazzi
    R Padrini
    British Journal of Cancer, 2009, 100 : 1549 - 1557
  • [36] LEVELS OF 5-FLUOROURACIL (5FU) IN PLASMA OF PATIENTS TREATED BY DRUG INFUSION
    HILLCOAT, BL
    MCCULLOCH, PB
    FIGUEREDO, A
    ROSENFELD, J
    KAWAI, M
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1976, 17 (MAR): : 199 - 199
  • [37] Phase I study of weekly oxaliplatin (OXA)+5-fluorouracil continuous infusion (FU CI) in patients (pts) with advanced colorectal cancer (CRC).
    Pasetto, LM
    Lonardi, S
    Sartor, L
    Brandes, AA
    Sileni, VC
    Caroti, C
    D'Amico, M
    Gallo, L
    Monfardini, S
    Aschele, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 311S - 311S
  • [38] Toxicity profile following adjuvant therapy using CPT-11, 5-fluorouracil (5FU) and leucovorin (LV) in patients with rectal cancer.
    Kalofonos, HP
    Kardamakis, D
    Bamias, A
    Papakostas, P
    Timotheadou, E
    Samelis, G
    Xiros, N
    Pavlidis, N
    Skarlos, D
    Fountzilas, G
    ANNALS OF ONCOLOGY, 2000, 11 : 46 - 47
  • [39] Dihydropyrimidine dehydrogenase (DPD) evaluation in 5-fluorouracil (5FU)-based therapies for gastrointestinal (GIC) and breast cancer (BC) patients (pts)
    Marchetti, P.
    Paris, I.
    Cappellini, G. Antonini
    Romiti, A.
    Malaguti, P.
    Viterbo, A.
    De Blasi, A.
    Lostia, A. M.
    Lionetto, L.
    Simmaco, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] INHIBITION OF THE TOXIC ACTIVITY OF 5-FLUOROURACIL (5FU) WITH HYPOTHERMIA
    GAREGNANI, TC
    BARCAT, JA
    MEDICINA-BUENOS AIRES, 1986, 46 (05) : 599 - 600
12345